Who
Michael Gray
CFO and COO
Company insider
Files Form 4 as: CFO and COO, Upstream Bio; CFO & COO, Enliven Therapeutics; President, CEO and CFO, X4 Pharmaceuticals; CFO, Curis.
In numbers
- Trades disclosed
- 65
- Buys
- 1
- Sells
- 9
- Bought
- $29K
- Sold
- $454K
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 31 May 2006
- Last trade
- 16 Sep 2026
- Last filed
- 17 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 17 Sep 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $4,683853 at $5.49 | filing |
| 16 Sep 2026filed 17 Sep 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $4,683853 at $5.49 | filing |
| 16 Jun 2026filed 17 Jun 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $5,203853 at $6.10 | filing |
| 16 Jun 2026filed 17 Jun 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $5,203853 at $6.10 | filing |
| 16 Mar 2026filed 17 Mar 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $7,915852 at $9.29 | filing |
| 16 Mar 2026filed 17 Mar 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Sold | $7,915852 at $9.29 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Code A | —30,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —91,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —91,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | UPB Upstream BioBiotechnology | SEC FORM 4 Code A | —30,500 at $0.00 | filing |
| 6 Feb 2025filed 7 Feb 2025 | UPB Upstream Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 22 Feb 2023filed 22 Feb 2023 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $46K9,856 at $4.67 | filing |
| 30 Jan 2023filed 1 Feb 2023 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $14K3,596 at $3.92 | filing |
| 28 Jan 2022filed 1 Feb 2022 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,350 at $0.00 | filing |
| 28 Jan 2022filed 1 Feb 2022 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code A | —39,350 at $0.00 | filing |
| 26 Jan 2021filed 28 Jan 2021 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,800 at $0.00 | filing |
| 11 Dec 2020filed 15 Dec 2020 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,250 at $0.00 | filing |
| 11 Dec 2020filed 15 Dec 2020 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code M | $6,1501,250 at $4.92 | filing |
| 11 Dec 2020filed 15 Dec 2020 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $31K1,250 at $25.00 | filing |
| 27 Nov 2018filed 28 Nov 2018 | XFOR X4 PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
News
Ionis Pharmaceuticals (NASDAQ:IONS) & Upstream Bio (NASDAQ:UPB) Head to Head ReviewUPB · dailypolitical.com · 13 Oct 2026Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)UPB · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Michael Gray; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.